TKNO

Alpha Teknova

Stock NASDAQ – Stock Market Prices, News & Analysis

Alpha Teknova Inc. provides essential consumable materials for biotechnology and medical research, particularly in the fields of genomics and microbiology.

$ 3.12
1.27 %

Alpha Teknova

$ 3.12
1.27 %
TKNO

Alpha Teknova Inc. provides essential consumable materials for biotechnology and medical research, particularly in the fields of genomics and microbiology.

Price history of Alpha Teknova
Price history of Alpha Teknova

Performance & Momentum

6 Months 40.46 %
1 Year 30.82 %
3 Years 29.46 %
5 Years 87.52 %

Strategic Analysis

Alpha Teknova • 2026

Alpha Teknova Inc positions itself as a key supplier of essential consumables for biotechnology and medical research, specializing in genomics and microbiology. Its model relies on customer loyalty among specialized scientific clients and the provision of recurring products in a highly innovative yet fiercely competitive sector.

Strengths
  • Specialized niche in sought-after segments such as genomics and microbiology
  • Strategic supplier role for medical research laboratories
  • Recurring customer base linked to the consumable nature of the products
Weaknesses
  • Weakened financial position with sustained strong performance decline in the medium and long term
  • Lack of recent news likely to reinvigorate market momentum
Momentum

The momentum is currently very weak, indicating a loss of attractiveness for investors and a marked decline in share prices over the medium and long term. The adverse dynamics necessitate increased caution and the need for a significant operational or strategic turnaround to reverse the trend.

Analysis performed 4 weeks ago

Similar stocks to Alpha Teknova

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone